Home›Stock Screener›Alembic Pharmaceuticals

Alembic Pharmaceuticals Share Price Today | Stock Price & Alembic Pharmaceuticals Share Screener

APLLTD Pharmaceuticals & Biotechnology
Live Share Price NSE
₹1049.60
▲ 5.25 (0.50%)
2026-11-19 00:00:00
Live Share Price BSE
₹1048.75
▲ 5.20 (0.50%)
2026-11-19 00:00:00

As of November 19, 2026, the live Alembic Pharmaceuticals share price (NSE: APLLTD) is ₹1,049.60 on NSE and ₹1,048.75 on BSE, up 0.50% from the previous close, with shares trading between ₹1,038.50 and ₹1,054.25 in today's trading session, and a 52-week range of ₹646.55–₹1,057.10. Track Alembic Pharmaceuticals marketcap in USD to gauge the company's total market size. Use the Alembic Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Alembic Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹1,874 and net income of ₹202, with EBITDA of ₹230, an operating margin of 11.0% and a profit margin of 10.8%.

Alembic Pharmaceuticals Market Cap ₹20,778.69 Cr.
APLLTD P/E Ratio (TTM) 24.10
Alembic Pharmaceuticals P/B Ratio 3.40
EPS (TTM) ₹34.33
Dividend Yield 1.16%
Debt to Equity 0.25
APLLTD 52 Week High ₹1057.10
Alembic Pharmaceuticals 52 Week Low ₹646.55
Operating Margin 11.00%
Profit Margin 10.78%
APLLTD Revenue (TTM) ₹1,874.00
EBITDA ₹230.00
Net Income ₹202.00
Total Assets ₹8,763.00
Total Equity ₹5,669.00

Alembic Pharmaceuticals Share Price Chart

Track the current stock price of Alembic Pharmaceuticals with an interactive chart. Analyse APLLTD share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Alembic Pharmaceuticals stock quote in one place.

The quote of ₹1,049.60 sits between the 52-week low of ₹646.55 and the 52-week high of ₹1,057.10, and the latest session moved 0.50% from the previous close.

Alembic Pharmaceuticals Company Profile - Fundamental Screener

Screen Alembic Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for APLLTD shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, with C R Amin listed as chairperson or CEO, and it trades under ISIN INE901L01018.

Business Overview

Alembic Pharmaceuticals is an India-based company that manufactures and markets generic pharmaceutical products globally. It operates in India Formulations, International Generics, and Active Pharmaceutical Ingredients (API) segments. The company has state-of-the-art research and manufacturing facilities approved by regulatory authorities, including the US FDA. Alembic produces a range of generics across...more

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

Chairperson/CEO C R Amin
ISIN INE901L01018

Alembic Pharmaceuticals Balance Sheet Screener

Screen APLLTD balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹8,763, up from ₹7,773 in 2025.

Latest statistics put total assets at ₹8,763 and shareholder funds at ₹5,669, with a leverage ratio of 0.25.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 8,763 7,773 6,446 6,183 7,122 6,709 5,989 4,778 3,941 2,689
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 3,081 2,524 2,547 2,398 1,798 1,788 1,552 1,159 993 799

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 500 171 172 175 168 361 1,047 570 576 94
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 5,669 5,190 4,818 4,371 5,238 5,067 3,190 2,718 2,220 1,902
Share Capital 39 39 39 39 39 39 38 38 38 38
Reserves & Surplus 5,636 5,152 4,779 4,331 5,198 5,028 3,182 2,681 2,182 1,865

Alembic Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis

Screen Alembic Pharmaceuticals income statement and profit fundamentals. Analyze APLLTD quarterly results. Alembic Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹1,874 and net profit was ₹202, equal to earnings per unit of ₹10.31, at an operating margin of 11%.

In that period expenses were ₹1,645, interest cost ₹23 and tax ₹-83. The next period listed, 2026-Jun, shows revenue of ₹2,165 and net profit of ₹172.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec

Revenue and Expenses

Revenue 1,874 2,165 2,619 1,784 1,717 1,919 1,892 1,521 1,564 1,678 1,703 1,407 1,498 1,605 1,634
Expenses 1,645 1,818 2,042 1,498 1,430 1,595 1,627 1,257 1,325 1,409 1,433 1,203 1,288 1,387 1,364

Operating Costs and Margins

EBITDA 230 347 577 286 287 324 265 263 239 270 270 205 210 218 269
Operating Profit % 11.00% 15.00% 22.00% 15.00% 16.00% 17.00% 13.00% 17.00% 15.00% 15.00% 15.00% 14.00% 13.00% 13.00% 16.00%
Depreciation 89 98 101 69 74 76 80 70 69 71 70 74 66 68 69
Interest 23 28 38 25 24 24 23 11 13 19 22 14 14 16 15

Profit and Earnings

Profit Before Tax 119 222 438 192 190 224 162 183 157 180 178 116 130 135 185
Tax -83 50 104 35 37 40 30 5 23 27 40 -36 9 -2 4
Net Profit 202 172 334 157 154 184 132 178 135 153 138 153 121 137 180
EPS 10.31 8.80 17.05 7.98 7.85 9.40 6.76 9.07 6.84 7.79 7.01 7.76 6.14 6.95 9.23

Alembic Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals

Screen APLLTD cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹783, and net cash flow was an inflow of ₹113.

Over the same period, investing activities used ₹506 and financing activities used ₹164.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 783 88 803 724 552 1,463 449 812 312 329
Investing Activities -506 -568 -321 -448 -372 -840 -731 -756 -884 -486

Financing and Net Cash

Financing Activities -164 444 -438 -262 -217 -597 155 59 503 -129
Net Cash Flow 113 -37 45 14 -37 26 -127 115 -69 -286

Alembic Pharmaceuticals Shareholding Pattern Screener

See Alembic Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Alembic Pharmaceuticals promoter holding and ownership changes for APLLTD on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 69.74%, foreign institutions 4.25%, domestic institutions 16.18% and the public 6.86%, spread across 86,432 shareholders.

The shareholder count was 86,432 in 2026-Mar, compared with 86,796 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 69.74% 69.87% 69.87% 69.67% 69.67% 69.74% 69.74% 69.61%

Institutional Investors

FII Holding 4.25% 4.18% 4.55% 3.94% 3.96% 4.05% 4.24% 4.46%
DII Holding 16.18% 15.94% 15.43% 16.43% 16.46% 16.30% 16.17% 15.38%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 6.86% 6.97% 7.00% 7.07% 7.01% 6.93% 6.87% 7.41%
Other Holding 2.96% 3.03% 3.15% 2.88% 2.89% 2.99% 2.98% 3.14%
Shareholder Count 86,432 86,796 86,532 91,336 89,013 89,969 87,000 76,567

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Alembic Pharmaceuticals. Alembic Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹12.00 per unit for 2026-March, a yield of 1.16%, compared with ₹11.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹12.00, ₹11.00 and ₹11.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹12.00 1.16%
2025-March ₹11.00 1.66%
2024-March ₹11.00 1.18%
2023-March ₹8.00 0.81%
2022-March ₹10.00 2.13%
2021-March ₹14.00 1.89%
2020-March ₹10.00 1.04%
2019-March ₹5.50 1.03%
2018-March ₹4.00 0.74%
2017-March ₹4.00 0.73%

Alembic Pharmaceuticals Stock Index Membership - Nifty & Sensex

See which indices include Alembic Pharmaceuticals stock. Check APLLTD index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 16 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX BSE500, BSE INDEX MSL400.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
NIFTY 500
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY SMALLCAP250 MOMENTUM QUALITY 100
NIFTY SMLCAP 250
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP
NIFTY500 SHARIAH

Alembic Pharmaceuticals Market Events Screener - Corporate Actions

Get Alembic Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Alembic Pharmaceuticals stock events that may affect APLLTD share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 4, 2026, with a record date of November 4, 2026.

It is followed by Annual General Meeting dated August 5, 2026 and Quarterly Result Announcement dated August 4, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-04 2026-11-04 Quarterly Result Announcement NA 4.86%
2026-08-05 2026-08-05 Annual General Meeting NA -0.83%
2026-08-04 2026-08-04 Quarterly Result Announcement NA 1.47%
2026-07-29 2026-07-29 Dividend ₹ 12.00 /share 4.12%
2026-05-15 2026-05-15 Quarterly Result Announcement NA 4.71%
2026-02-05 2026-02-05 Quarterly Result Announcement NA 3.71%
2025-11-04 2025-11-04 Quarterly Result Announcement NA -0.92%
2025-08-05 2025-08-05 Annual General Meeting NA -1.57%
2025-08-05 2025-08-05 Quarterly Result Announcement NA -6.22%
2025-07-29 2025-07-29 Dividend ₹ 11.00 /share 10.49%
2025-05-06 2025-05-06 Quarterly Result Announcement NA 6.54%
2025-02-03 2025-02-03 Quarterly Result Announcement NA -9.02%
2024-11-07 2024-11-07 Quarterly Result Announcement NA -3.68%
2024-07-22 2024-07-22 Annual General Meeting NA 27.73%
2024-07-15 2024-07-15 Dividend ₹ 11.00 /share -1.72%

Alembic Pharmaceuticals Competitors Screener - Peer Stocks Comparison

Screen APLLTD competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 448,076 41.10 61,674 12.69% 11,565 59.98
Divis Laboratories 294,139 90.70 11,067 13.95% 2,568 67.88
Torrent Pharmaceuticals 178,438 84.50 13,886 20.34% 2,138 49.31
Laurus Labs 119,949 98.10 6,868 22.01% 890 49.19
Zydus Life Science 118,902 27.60 27,658 17.64% 5,026 52.87
Dr Reddys Laboratories 115,011 41.70 35,059 3.90% 4,158 69.34
Cipla 112,656 39.40 29,045 2.24% 3,870 55.82
Mankind Pharma 108,490 48.40 14,636 14.85% 1,938 63.62
Aurobindo Pharma 103,223 26.40 34,145 5.56% 3,503 60.38
Lupin 90,393 17.30 29,039 26.75% 5,356 44.23

Alembic Pharmaceuticals Company Announcements - News & Reports Screener

Screen APLLTD latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 18, 2026.

The next most recent announcements are dated November 14, 2026 and November 5, 2026.

Date Update Actions
2026-11-18 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-11-14 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-11-05 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-04 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-11-04 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-04 Updated Contact Details Of Key Managerial Personnel Pursuant To Regulation 30(5) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. -
2026-11-04 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-11-04 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-11-04 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-11-04 Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026 -
2026-11-04 Board Meeting Outcome for Outcome Of Board Meeting Held On 4Th November 2026 -
2026-11-02 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-30 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-30 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-10-28 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-28 Board Meeting Intimation for Considering Unaudited Financial Results For The Quarter And Half Year Ended 30Th September 2026. -
2026-10-28 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-10-27 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-10-19 Intimation Under Regulation 30 Of SEBI LODR Regulations 2015 -
2026-10-17 Announcement under Regulation 30 (LODR)-Press Release / Media Release -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹1,049.60, within a 52-week range of ₹646.55 to ₹1,057.10. The P/E ratio is 24.10 and the P/B ratio is 3.40, with earnings per unit of ₹34.33. Market capitalisation stands at ₹20,778.69 Cr and the dividend yield is 1.16%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.